Shopping Cart

Your shopping cart is currently empty

Elarofiban (Synonyms: RWJ-53308, RWJ53308, RWJ 53308)

Name: Elarofiban
Brand: TargetMol
SKU: T27250
Price: 397 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No. T27250 Copy Product Info

Purity: 98.76%

🥰Excellent

Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.

Elarofiban

Copy Product Info

🥰Excellent

Catalog No. T27250

Synonyms RWJ-53308, RWJ53308, RWJ 53308

Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.

Cas No. 198958-88-2

Pack Size	Price	USA Stock	Global Stock
1 mg	$397	In Stock	In Stock
5 mg	$970	In Stock	In Stock
10 mg	$1,290	-	In Stock
25 mg	$1,950	-	In Stock
50 mg	$2,620	-	In Stock
100 mg	$3,530	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

Custom-made molecule. TargetMol’s expert synthesis team delivers cost-effective solutions. Contact us for inquiries. Committed to serving you.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:98.76%

ee:99.66%

Appearance:Solid

Color:Yellow

Resource Download

COA HPLC CSFC ORP HNMR

Product Introduction

Bioactivity

Description	Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.
In vitro	Elarofiban (RWJ-53308) is a novel nonpeptide glycoprotein IIb/IIIa (GPIIb/IIIa) antagonist that inhibits fibrinogen binding to GPIIb/IIIa with an IC(50) of 0.4+/-0.3 nM. RWJ-53308 inhibits thrombin-induced platelet aggregation in human gel-filtered platelets (IC(50)=60+/-12 nM) and platelet aggregation in human platelet-rich plasma (PRP) in response to collagen, arachidonic acid, ADP, and SFLLRN-NH(2) (IC(50)=60+/-10, 150+/-30, 70+/-4, and 160+/-80 nM, respectively).[4]
In vivo	The potency of Elarofiban (RWJ-53308) in dog and guinea pig PRP is similar to human PRP. RWJ-53308 inhibits ex vivo collagen- and ADP-induced platelet aggregation in conscious dogs for up to 4 h following 0.3 mg/kg iv, and through 4 and 6 h following 1 and 3 mg/kg po. Oral bioavailability is 16+/-7%. RWJ-53308 reduces thrombus weight in a canine arteriovenous (AV) shunt model following intravenous (0.01-0.1 mg/kg) and oral (3 mg/kg) administration. In a guinea pig carotid artery pinch-injury model, RWJ-53308 completely suppresses thrombus-induced cyclic flow reductions (CFR) at 0.7 mg/kg iv. RWJ-53308 also blocks thrombus formation in photoactivation- and ferric chloride-induced models of thrombosis in guinea pigs at 0.3 and 1 mg/kg iv, respectively. In summary, RWJ-53308 is a potent orally active GPIIb/IIIa antagonist that may be useful for both acute and chronic treatment of arterial thrombotic disorders.[4]
Synonyms	RWJ-53308, RWJ53308, RWJ 53308

Chemical Properties

Molecular Weight	416.51
Formula	C₂₂H₃₂N₄O₄
Cas No.	198958-88-2
Smiles	[C@H](NC(=O)[C@H]1CN(C(CCC2CCNCC2)=O)CCC1)(CC(O)=O)C=3C=CC=NC3
Relative Density.	1.203 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 60 mg/mL (144.05 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.4009 mL	12.0045 mL	24.0090 mL	120.0451 mL
5 mM	0.4802 mL	2.4009 mL	4.8018 mL	24.0090 mL
10 mM	0.2401 mL	1.2005 mL	2.4009 mL	12.0045 mL
20 mM	0.1200 mL	0.6002 mL	1.2005 mL	6.0023 mL
50 mM	0.0480 mL	0.2401 mL	0.4802 mL	2.4009 mL
100 mM	0.0240 mL	0.1200 mL	0.2401 mL	1.2005 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc